Literature DB >> 12874784

By-products of immunoglobulin somatic hypermutation.

Mats Bemark1, Michael S Neuberger.   

Abstract

The antigen receptor loci are the only loci in humans to undergo programmed somatic gene modification. Although aberrant V(D)J integration and class switch recombination can both give rise to chromosomal translocations, a role for somatic hypermutation in such genomic rearrangements has been suggested but is less clearly established. To characterize the types of by-products of somatic hypermutation, we analyzed aberrant rearrangements involving the immunoglobulin loci in a human B-cell line (Ramos) that performs Ig V gene hypermutation constitutively during culture. Single-nucleotide substitutions account for 95% of the mutational events in the VH gene, with small deletions and duplications accounting for most of the remaining mutations. However, larger genetic alterations can be detected at low frequency, accounting for 0.5% of VH-inactivating mutations. Examples include a large (13 kb) deletion, which entirely removes the expressed VH gene; a 3-kb deletion extending from the functional VHDJH into an upstream VH (generating a hybrid VHDJH gene reminiscent of VH replacement); and an ectopic insertion into the VH from chromosome 1. The results support the proposal that aberrant antibody hypermutation can lead to gross genomic alterations but indicate that such events are rare. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874784     DOI: 10.1002/gcc.10241

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  JH6 downstream intronic sequence is dispensable for RNA polymerase II accumulation and somatic hypermutation of the variable gene in Ramos cells.

Authors:  Diana P Castiblanco; Darrell D Norton; Robert W Maul; Patricia J Gearhart
Journal:  Mol Immunol       Date:  2018-04-04       Impact factor: 4.407

Review 2.  Immunoglobulins in teleosts.

Authors:  Sumaira Bilal; Angela Etayo; Ivar Hordvik
Journal:  Immunogenetics       Date:  2021-01-13       Impact factor: 2.846

Review 3.  Targeting the N332-supersite of the HIV-1 envelope for vaccine design.

Authors:  Thandeka Moyo; Dale Kitchin; Penny L Moore
Journal:  Expert Opin Ther Targets       Date:  2020-04-27       Impact factor: 6.902

4.  Checkpoint kinase 2 is required for efficient immunoglobulin diversification.

Authors:  Kathrin Davari; Samantha Frankenberger; Angelika Schmidt; Nils-Sebastian Tomi; Berit Jungnickel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  A classification model for distinguishing copy number variants from cancer-related alterations.

Authors:  Irina Ostrovnaya; Gouri Nanjangud; Adam B Olshen
Journal:  BMC Bioinformatics       Date:  2010-06-02       Impact factor: 3.169

Review 6.  Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells.

Authors:  Sumedha Roy; Yuan Zhuang
Journal:  Front Med       Date:  2018-07-24       Impact factor: 4.592

7.  DNA Breaks in Ig V Regions Are Predominantly Single Stranded and Are Generated by UNG and MSH6 DNA Repair Pathways.

Authors:  Kimberly J Zanotti; Robert W Maul; William Yang; Patricia J Gearhart
Journal:  J Immunol       Date:  2019-01-21       Impact factor: 5.422

8.  Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity.

Authors:  B S Briney; J R Willis; J E Crowe
Journal:  Genes Immun       Date:  2012-06-21       Impact factor: 2.676

Review 9.  AID to overcome the limitations of genomic information by introducing somatic DNA alterations.

Authors:  Tasuku Honjo; Masamichi Muramatsu; Hitoshi Nagaoka; Kazuo Kinoshita; Reiko Shinkura
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2006-05       Impact factor: 3.493

10.  Secondary mechanisms of diversification in the human antibody repertoire.

Authors:  Bryan S Briney; James E Crowe
Journal:  Front Immunol       Date:  2013-03-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.